Regeneron Stock Drops 034% on 626 Billion Share Volume Day Ranking 118th

On May 5, 2025, Regeneron Pharmaceuticals, Inc. (REGN) experienced a significant decline in its stock price, dropping by 0.34%. The trading volume for the day was substantial, with a total of 6.26 billion shares exchanged, placing it at the 118th position in terms of trading volume for the day.

Regeneron's stock price has been subject to various analyst ratings and price targets. According to 23 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $907.39, which represents an increase of 49.83% from the current price. Additionally, the 12-month average price target based on analyst ratings is $807.90, indicating a 33.40% upside potential.

Recent adjustments to price targets by analysts have also impacted investor sentiment. BMO reduced its price target for Regeneron from $865 to $800, while Evercore ISI lowered its target from $950 to $900. These revisions reflect the market's cautious outlook on the company's future performance.

Despite the recent decline, Regeneron's stock has shown resilience in the face of broader market fluctuations. Following a week where the broader market witnessed a 2.7% rise, Regeneron's stock nudged up 1.86%. This performance highlights the company's ability to navigate market volatility and maintain investor confidence.